JDRF is the leading funding organisation in Type 1 Diabetes (T1D) research. Our mission is a world without T1D and our mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. JDRF collaborates with a wide spectrum of partners at every stage of the drug and device delivery pipeline and is the only organization with the scientific resources regulatory influence and strategic plan to deliver a world without T1D. JDRF’s influence and leadership extends beyond funding research. We strategically partner with industry, governments, foundations, academia and clinicians, because curing T1D is a global, coordinated effort.
JDRF has expertise and establishes strategic roadmaps in Artificial Pancreas System, Beta cell replacement, beta cell regeneration, immunotherapy, screening of T1D, prevention and treatment of diabetic nephropathy and diabetic retinopathy and therapies for psychosocial burden of living with T1D.
Role within MELISSA
Role of the institution within MELISSA: JDRF’S role in MELISSA is to include the patients perspective in all Work-Packages (WPs). Towards this goal, JDRF assists in the composition and invitation of the PAC and accompany their meeting. The PAC will be led by JDRF and will be comprised of 8 patient representatives affected by type 1 or type 2 diabetes. The PAC’s role is to advise the WPs to ensure that the patient perspective is included on the work conducted and guarantee the return to patients. The PAC will therefore closely collaborate with the WP leads and meet regularly with the WPs to guarantee close involvement in project activities. Throughout the project JDRF will facilitate a positive and productive communication between the PAC members and the WP leads.